The goals of this study were to determine the cellular sites of insulin-like growth factor (IGF) and IGF type-I receptor (IGF-IR) expression and to begin to elucidate functional roles for the IGFs during postnatal development of the murine mammary gland. Using in situ hybridization analyses, we determined that IGF-I, IGF-II, and IGF-IR messenger RNAs were expressed in the highly proliferative terminal end buds during pubertal ductal growth. Consistent with these data, IGF-I (in combination with mammogenic hormones) promoted ductal growth in pubertal stage mammary glands cultured in vitro. During postpubertal and pregnancy stages, IGF-II and IGF-IR continued to be expressed in ductal epithelium. Expression of IGF-II in ductal and alveolar epithelium correlated with the pattern of rapidly proliferating cells, as determined by incorporation of 5-Bromo-2Ј-deoxyuridine, suggesting a potential autocrine or paracrine role for IGF-II as a mitogen for ductal epithelial cells. IGF-I expression was reinitiated in mammary epithelium in the differentiated alveoli at the end of pregnancy, suggesting an additional role for this factor in maintenance of the alveoli during lactation. Taken together, these data support an in vivo role for locally-produced IGFs in promoting ductal growth during puberty and suggest that IGF-I and IGF-II may have distinct functions during pregnancy-induced alveolar development. (Endocrinology 140: 454 -461, 1999) 
in ductal and alveolar epithelium correlated with the pattern of rapidly proliferating cells, as determined by incorporation of 5-Bromo-2Ј-deoxyuridine, suggesting a potential autocrine or paracrine role for IGF-II as a mitogen for ductal epithelial cells. IGF-I expression was reinitiated in mammary epithelium in the differentiated alveoli at the end of pregnancy, suggesting an additional role for this factor in maintenance of the alveoli during lactation. Taken together, these data support an in vivo role for locally-produced IGFs in promoting ductal growth during puberty and suggest that IGF-I and IGF-II may have distinct functions during pregnancy-induced alveolar development. (Endocrinology 140: 454 -461, 1999) P OSTNATAL growth of the mammary gland in rodents is initiated at puberty, under the influence of ovarian and pituitary hormones (1) (2) (3) (4) (5) . Before puberty, the mammary gland consists of a rudimentary epithelial structure that has initiated growth into the mammary fat pad (1, 2) . Pubertal growth of the mammary epithelium involves rapid lengthening and branching of the ductal structures, primarily through proliferation of cells in the terminal end buds (TEBs) located at the tips of the growing epithelial ducts. Postpubertal virgin glands undergo continued moderate epithelial growth with each estrus cycle, that consists of further branching and the formation of rudimentary alveolar structures (1, 2, 6) . The second major postnatal growth phase of the mammary gland occurs during pregnancy, under the influence primarily of ovarian hormones and pituitary PRL (1, 4, (7) (8) (9) (10) (11) (12) (13) (14) . Pregnancy-induced growth results in terminal differentiation of the gland and culminates in formation of secretory alveoli in preparation for lactation. Terminal differentiation of the gland is then maintained throughout lactation until weaning and involution, the process whereby the alveolar structures regress through remodeling and programmed cell death.
The ovarian and pituitary hormones mediate postnatal growth of the mammary gland, at least in part, through local induction of peptide growth factors (1) . The insulin-like growth factors (IGFs) are among the growth factors implicated in postnatal growth of the mammary gland. IGF-I and IGF-II are mitogenic peptides that have essential growth promoting actions during embryonic development (15, 16) . The evidence that the IGF peptides have a role in postnatal development of mammary tissue comes from in vitro as well as in vivo studies. In vitro, both IGF-I and IGF-II are potent mitogens for normal and tumorigenic mammary epithelial cells (17) (18) (19) (20) . Moreover, conditions for optimal growth of mammary gland explant cultures use micromolar concentrations of insulin (13, (21) (22) (23) . At these superphysiological concentrations, insulin stimulates the IGF type I receptor (IGF-IR), the primary signaling receptor for both IGF-I and IGF-II (24) . In vivo, IGF-I (implanted into mammary fat pads of hypophysectomized, estrogen-treated male rats) induces epithelial growth (25) .
Endogenous production of IGF-I is likely an important component of GH, as well as estrogen-mediated mammary development. Administration of GH to hypophysectomized rats induces ductal and alveolar growth, as well as a dosedependent increase in mammary expression of IGF-I messenger RNA (mRNA) (26 -28) . IGF-I also synergizes with estrogen to stimulate ductal growth when coimplanted into glands of hypophysectomized, ovariectomized female rats (27, 29) . The mechanism for this synergism is unknown; however, evidence that IGF-I induces transcription of the estrogen receptor in breast cancer cell lines suggests that IGF-I may enhance estrogen responsiveness of mammary tissue (30) . These studies support a model for IGF-I action in postnatal mammary growth as a downstream mediator of GH that, once induced, amplifies the mammogenic actions of estrogen.
In addition to its role as a mitogen for mammary epithelium, exogenous IGF-I promotes survival of mammary epithelial cells in vitro (31) , and mammary overexpression of IGF-I in transgenic mice results in impaired involution caused by disruption of the normal process of cell death in mammary epithelium (32, 33) . These results suggest that a reduction in IGF-I levels may be important for normal involution of the mammary gland.
Although in vivo and in vitro manipulations with exogenously added IGFs support the hypothesis that these factors have important endogenous roles in mammary epithelial growth, defining the spatial and temporal patterns of IGF and IGF-IR expression is critical for determining the precise roles for these factors in normal development of the mammary gland. Endogenous expression patterns for other growth factors and receptors implicated in mammary development have been well documented, including those for EGF/TGF-␣ (34 -36), the TGF-␤s (37, 38) , and FGFs (39) . In contrast, very little is known about the endogenous expression of the IGFs and the IGF-IR during postnatal stages of mammary growth.
To determine the spatial and temporal expression of the IGFs and the IGF-IR during normal postnatal growth of the mammary gland, we have used in situ hybridization (ISH) to identify cellular sites of the mRNAs for these genes in the mouse mammary gland during the rapid growth phases of puberty and pregnancy. Results of these studies are presented here and demonstrate that IGF-I, IGF-II, and IGF-IR mRNA expression patterns are consistent with a role for the IGFs in TEB proliferation during pubertal growth. Moreover, using a whole-organ culture system, we also demonstrate that IGF-I induces ductal growth in mammary glands stimulated with mammogenic hormones in the presence of nanomolar levels of insulin. In contrast, EGF (under identical conditions) failed to stimulate ductal growth. Finally, a surprising finding from these studies is the demonstration that IGF-II mRNA is a major component of ductal epithelium during both pubertal and pregnancy-induced growth and is expressed in a pattern that correlates with the pattern of highly proliferative cells along the ducts. In contrast, IGF-I mRNA expression is restricted to the stroma, except for the TEBs during puberty and the differentiated alveoli in late pregnancy. These results suggest distinct roles for IGF-I and IGF-II during postnatal development of the mammary gland.
Materials and Methods

Radioactive ISH
Abdominal mammary glands were removed from C57Bl6/J virgin female mice at either 5.5 or 15 weeks of age or from C57Bl6/J female mice at midgestation (days 12-13) or late gestation (days 17-18) of pregnancy. The day after copulation was counted as day 1 of pregnancy. For optimal hybridization signal, tissues for ISH analyzes of the IGFs and IGF-IR were fresh-frozen in isopentane on dry ice and stored at Ϫ80 C before cryostat sectioning. For ISH analyzes, frozen cryostat sections were removed from Ϫ80 C and immediately postfixed for 10 min in 4% paraformaldehyde/PBS, rinsed in PBS, and dehydrated through ethanols. The sections were then acetylated in 0.25% acetic anhydride (vol/vol) in 0.05 m triethanolamine (pH 8.0), washed in 0.2 ϫ SSC (1 ϫ SSC contains 0.15 m NaCl and 0.015 m sodium citrate), and dehydrated through ethanols. Sections were prehybridized for 2-3 h at room temperature (RT) in a solution containing 50% (vol/vol) deionized formamide, 0.6 m sodium chloride, 10 mm Tris (pH7.5), 1 mm EDTA, 0.02% Ficoll, 0.02% BSA (fraction V), 0.02% polyvinylpyrrolidone, 0.5 mg/ml sheared herring sperm DNA, 0.5 mg/ml yeast total RNA, and 0.05 mg/ml yeast transfer RNA. Hybridization was carried out at 50 C overnight in prehybridization buffer containing 0.1 mg/ml herring sperm DNA with the addition of 10% dextran sulfate, 10 mm dithiothreitol, 0.1% SDS, and 35 S-labeled complementary RNA probe (4 ϫ 10 7 cpm/ml). After hybridization, the sections were rinsed in 2 ϫ SSC and washed for 30 min at 45 C in 50% deionized formamide/1 ϫ SSC/10 mm dithiothreitol. Unhybridized probe was removed by treatment with ribonuclease (RNase) A (100 mg/ml in 0.5 m NaCl, 10 mm Tris (pH 7.5), 1 mm EDTA) for 30 min at RT, followed by a 2-h wash in 0.2 ϫ SSC at 55-60 C. After the high stringency wash, the sections were dehydrated through ethanols and coated with autoradiographic emulsion (NTB2, Eastman Kodak Co., Rochester, NY), diluted 1:1 with deionized-distilled water. Slides were stored at 4 C in a desiccated light-proof box for 4 -8 weeks. After exposure, the slides were developed (Kodak D19, 3.5 min, 15 C), rinsed in H 2 O, and fixed (15 C in Kodak fixer for 5-6 min). Sections were washed extensively in H 2 O, counterstained with hematoxylin, dehydrated through graded ethanols and xylene, and coverslipped with Permount mounting media (Fisher). All ISH analyzes were performed on at least 2-3 glands from each age. Hybridization with control (sense) RNA yielded very low background in all cases.
Nonradioactive ISH
Nonradioactive ISH was performed using Digoxigenin RNA probes (Boehringer Mannheim). Digoxigenin-labeled RNA probe for IGF-II was prepared according to standard protocols (Genius Kit, Boehringer Mannheim) using Digoxigenin-UTP undiluted with cold UTP. The procedure for nonradioactive ISH was as described above for ISH with radioactive probes, except for the following modifications: the hybridization temperature was 72 C, the concentration of the Digoxigeninlabeled probe was 0.4 mg/ml, and the slides were washed in 0.2 ϫ SSC at 72 C for 1 h after the hybridization followed by 0.2 ϫ SSC at RT for 5 min. Sections were then treated with ribonuclease (RNase) A (as described above), rinsed in RNase buffer without RNase A, and taken immediately into immunodetection for Digoxigenin. Immunodetection of Digoxigenin was performed according to Boehringer Genius Kit instructions (Boehringer Mannheim).
Detection of proliferating cells
Mice at days 12-13 of pregnancy were injected with 0.01 ml/g BW of a solution of 5-Bromo-2Ј-deoxyuridine and 5-Fluoro-2Ј-deoxyuridine (10:1 ratio, Amersham, Arlington Heights, IL). After 2.5 h, the tissues were perfusion-fixed with 4% paraformaldehyde, and abdominal mammary glands were removed, embedded in paraffin, and sectioned at 4 -5 microns. The sections were deparafinized through xylenes and ethanols, treated with 0.1% trypsin in 0.1 m Tris buffered saline plus 0.1% CaCl 2 for 20 min at 37 C, rinsed in PBS, and treated with 0.3% hydrogen peroxide in PBS for 10 min at RT to block endogenous peroxidase activity. Sections were then rinsed in PBS, treated with 2 n HCl for 1 h at 37 C, rinsed twice in 0.1 m borate buffer (pH 8.5), rinsed in PBS, and washed in 0.2% Triton X-100 for 30 min at RT. After additional rinses in PBS, sections were blocked for 1 h at RT in PGB superblock (10% BSA, 0.05% NaN 3 , 10% normal goat serum in PBS) and incubated for 2 h at 37 C with peroxidase-conjugated antibromodeoxyuridine (BrdU) antibody (1:15, Boehringer Mannheim) in PGB diluent (PGB superblock diluted 1:5 with 0.5 m phosphate buffer, pH 7.6). The sections were rinsed in PBS and incubated with inactive DAB (2.5 mg 3Ј-3Ј diaminobenzadine, 450 l NiCl 2 in PBS, pH 7.6) for 5 min, followed by activated DAB (inactive DAB solution, containing 7% H 2 O 2 ) for 10 min. Finally, the sections were washed in distilled H 2 O and coverslipped with AquaMount (Lerner Laboratories, Pittsburgh, PA).
Organ culture
Four-week-old C57Bl6/J female mice were estrogen-and progesterone-primed by implantation of 9-day time-release pellets of 3 mg progesterone and 3 g estrogen (Innovative Research of America, Sarasota, FL). After 9 days, the mice were killed by cervical dislocation, and two abdominal mammary glands were removed from each mouse, under sterile conditions. The glands were placed on Gelfoam (Upjohn, Kalamazoo, MI) in 6-well culture dishes, maintained at 37 C in 5% CO 2 in defined media, and fed every other day for 5 days. Defined media contained: Waymouth's medium (752/1 Gibco BRL, Gaithersburg, MD) plus 100 U/ml penicillin (Gibco BRL); 100 g/ml streptomycin (Gibco BRL); 5 g/ml PRL (ovine PRL NIH-P-S-12, obtained through the National Hormone Pituitary Program, NIDDK, NICHHD, USDA); 5 g/ml hydrocortisone (Sigma Chemical Co., St. Louis, MO); 1 g/ml aldosterone (Sigma Chemical Co.); and either 50 ng/ml insulin alone (Sigma Chemical Co.), 50 ng/ml insulin plus 100 ng/ml IGF-I (recombinant rat IGF-I; Gro-Pep, Adalaide, Australia), or 50 ng/ml insulin plus 60 ng/ml EGF (recombinant human EGF; Collaborative Research, Bedford, MA).
Whole-mount staining of mammary glands
Whole-mount staining of mammary glands was performed basically according to previously published procedures (44) . Briefly, mammary glands were removed from culture and placed in tissue cassettes between Whatman filter paper and sponges and were fixed overnight in 10% neutral buffered formalin. The glands then were washed 3 x 1 h in acetone, followed by 30 min each in 100% and 95% ethanol, and stained for 1.5 h in hematoxylin (0.13 g FeCl 3 , 13.5 ml H 2 O, 1.74 ml stock hematoxylin (10% hematoxylin in 95% ethanol), 200 ml 95% ethanol, pH 1.25). After staining, glands were soaked overnight in H 2 O, dehydrated in acidic 50% ethanol, and dehydrated through graded ethanols to xylene and photographed. Stained glands were stored at 4 C in methyl salicylate.
Results
Expression of IGFs during pubertal and postpubertal development
Radioactive ISH was used to determine the in vivo pattern of mRNA expression for IGF-I, IGF-II, and the IGF-IR in the murine mammary gland during pubertal (weeks 4 -8) and postpubertal virgin (Ͼ8 weeks) stages of growth. During the early pubertal phase of development (5-6 weeks of age), mRNAs for IGF-I, IGF-II, and the IGF-IR all were detectable in the TEBs of the epithelial ducts ( Fig. 1; A, C , and E). IGF-I mRNAs also were highly expressed in stroma surrounding the TEBs during pubertal growth (Fig. 1A) . In glands from both pubertal and postpubertal mice (15 weeks of age), IGF-II and IGF-IR mRNAs also were expressed in ductal epithelial cells (Fig. 1, D and F) . Expression of IGF-II mRNA in the postpubertal glands was nonuniform along the ductal epithelium (Fig. 1D) , whereas IGF-IR mRNAs were expressed uniformly along the ducts (Fig. 1F) . IGF-I mRNAs were lowto-undetectable along the ductal epithelium in postpubertal glands (Fig. 1B) when analyzed after longer exposure times (6 weeks) than those used to detect IGF-I mRNA in the TEBs (4 weeks).
Expression of the IGFs during pregnancyinduced development
At the peak of alveolar development in midpregnancy (day 12-13), expression of IGF-II mRNA (Fig. 2C) was detected in a punctate pattern along the ducts and in isolated alveolar cells. IGF-I mRNA expression ( Fig. 2A) was detectable in the epithelium at this age and in isolated stromal cells immediately surrounding the ducts. Expression of mRNAs for the milk proteins WDNM-1 (Fig. 2E) and ␤-casein (not shown) were readily detected in the developing alveoli. By day 18 of pregnancy, both IGF-I (Fig. 2B ) and IGF-IR (Fig. 2F ) mRNAs were widely expressed in ductal and alveolar epithelium, whereas expression of IGF-II (Fig. 2D ) was retained in a nonuniform pattern along the ducts, identical to the expression pattern observed during postpubertal (Fig. 1D) and midpregnancy (Fig. 2C) stages.
IGF-II expression along the ductal epithelium represents single cells and correlates with the pattern of rapidly proliferating cells
Using a nonradioactive method for ISH, we determined that the punctate expression of IGF-II along the ductal structures during midpregnancy was caused by expression of IGF-II mRNA in single epithelial cells (Fig. 3A) . To determine whether the expression pattern of IGF-II correlated with proliferating cells along the ductal epithelium, we used a 2.5-h pulse of BrdU to label rapidly proliferating cells in midpregnant mammary glands (Fig. 3B) . Detection of cells with an antibody to BrdU revealed individual cells along the ducts that had incorporated BrdU in a pattern similar to that of IGF-II expression. This is in contrast to the expression pattern for the milk protein genes (see Fig. 2E ), which were expressed predominantly in developing alveoli throughout the second half of pregnancy.
IGF-I stimulates ductal growth in mammary gland organ culture
Because previously published conditions used to promote growth of mammary epithelium in whole-gland organ culture included micromolar levels of insulin (13, (21) (22) (23) , we tested whether IGF-I in the presence of physiological levels of insulin (nanomolar range) could promote epithelial growth in cultured glands. Four-week-old C57Bl6/J female mice were primed with estrogen and progesterone for 9 days, and the mammary glands were removed and cultured in hormone-supplemented media containing one of the following treatments: 1) 50 ng/ml insulin; 2) 50 ng/ml insulin plus 100 ng/ml IGF-I; or 3) 50 ng/ml insulin plus 60 ng/ml EGF. Results from these studies demonstrated that the addition of IGF-I (Fig. 4B ) was sufficient to promote extensive ductal growth, compared with 50 ng/ml of insulin alone (Fig. 4A) . In contrast, addition of EGF to 50 ng/ml of insulin (Fig. 4C) did not promote growth of epithelial structures greater than that observed in glands cultured in nanomolar levels of insulin alone.
Discussion
Data presented here demonstrate endogenous expression of IGF-I, IGF-II, and their primary signaling receptor, the IGF-IR, in the murine mammary gland during postnatal phases of rapid epithelial growth. Although these results do not address levels or localization of protein expression for these genes, they do provide support for the hypothesis that locally synthesized IGFs are an important component of postnatal development of the mammary gland. First, the expression of both IGF-I and IGF-II in the TEBs coincident with mRNA expression of the IGF-IR during pubertal growth suggests a potential role for the IGFs in ductal growth. To test whether the IGFs could promote ductal growth in glands in vitro, we used a whole-organ culture system similar to that previously established by other investigators (13, (21) (22) (23) . Using this mammary culture system, we demonstrated that IGF-I promoted ductal elongation in intact pubertal glands cultured for 5 days in vitro. It is unclear whether IGF-I can entirely compensate for insulin in our system, where we analyzed ductal elongation. It should be noted that, in previous experiments investigating the effects of IGF-I on cultured mammary glands, it was shown that IGF-I had no effect on alveolar differentiation when added with either micromolar levels of insulin or in the absence of insulin (23) . In ongoing experiments in our laboratory, we are using a variety of parameters to analyze growth of glands cultured in IGF-I in the presence or absence of insulin. Data from these studies indicate that IGF-I can promote ductal extension equivalently in glands cultured in the presence or absence of nanomolar levels of insulin (data not shown). However, it is possible that there is increased cell death in glands in the absence of insulin, which may not be apparent by histological analysis alone after only several days in culture. A more quantitative analysis of proliferation and cell death, in the presence or absence of both insulin and IGF-I, is the focus of future studies in our laboratory.
It is interesting that, in contrast to IGF-I, EGF was unable
Photomicrographs showing ISH to IGF-I, IGF-II, IGF-IR, and WDNM-1 mRNAs in the midpregnant (day 13; A, C, and E) and late-pregnant (day 18; B, D, and F) mammary gland. IGF-I mRNA expression is detectable in the epithelium and isolated stromal cells at day 13 (A). By day 18 of pregnancy, IGF-I mRNA is readily detected throughout the epithelium of ducts and differentiated alveoli (B). Similar to IGF-I at day 18 of pregnancy, IGF-IR mRNA is present throughout the epithelium (F). IGF-II mRNA is detected in a punctate pattern along the ducts and in developing alveoli at both day 13 (C) and day 18 (D) of pregnancy. This is in contrast to the expression of mRNA for the milk protein gene, WDNM-1, which is found throughout differentiating alveoli (but not ductal epithelium) beginning during midpregnancy (E). Autoradiographic emulsion exposure times, using probes of equivalent specific activities on fresh-frozen sections, were as follows: A, 8 weeks; B, C, and D, 4 weeks; F, 2.5 weeks. The section shown in E is from a perfusion-fixed gland and was exposed to autoradiographic emulsion for 2 days. D, Ductal epithelium; A, alveoli; S, stroma. Size bar ϭ 50 microns.
to promote ductal growth in our culture experiments. These results were surprising for several reasons: 1) the EGF receptor is expressed in TEBs during pubertal growth (36); 2) EGF implanted into regressed pubertal mammary glands of ovariectomized mice induces the formation of TEBs and ductal growth (34, 45) ; and 3) previous studies, using a similar whole-organ culture system, used identical concentrations of EGF, in the presence of micromolar levels of insulin, to promote alveolar development (13) . Thus, the failure of EGF to induce ductal growth in our culture system suggests that EGF (or TGF-␣) may synergize with the IGFs in mediating ductal growth during puberty. In contrast to the in vivo EGF implant experiments, which were conducted in pituitaryintact animals, the glands in whole-organ culture were cultured in the absence of GH, which can stimulate endogenous expression of IGF-I in mammary glands (28) . Because signaling through the IGF-IR results in antiapoptotic as well as mitogenic effects in a variety of cell types (46 -52) , it is possible that the predominant action of the IGFs in the TEBs is to promote survival of TEB cells. TEB cells are known to have low rates of cell death, particularly in the outer cap cell layer (2, (53) (54) . Similarly, the failure of EGF to induce ductal growth in the absence of IGF-IR stimulation could be caused by decreased survival of mammary epithelial cells in the absence of either high levels of insulin or IGF-I. A role for IGF-I in survival of mammary epithelium during late pregnancy and lactational stages is suggested by the IGF-I expression data presented here, taken together with the previously published data on transgenic mice that overexpress IGF-I from a milk protein promoter (32, 33) . After the disappearance of the TEBs in postpubertal ages, IGF-I mRNA expression was detected only at low levels in mammary epithelium and isolated stromal cells. IGF-I mRNA expression increased in mammary epithelium in the differentiated alveoli at the end of pregnancy, coincident with high expression of IGF-IR mRNAs. These results are consistent with results showing that the major phenotype of IGF-I overexpression in pregnant mammary glands of transgenic mice was inhibition of cell death during involution (32, 33) .
A major and unexpected finding of this study was the high epithelial expression of IGF-II in the mammary gland throughout all stages of postnatal development. Though both IGF-I and IGF-II are potent mitogens for mammary epithelial cells in vitro, previously published results, supporting a role for the IGFs in postnatal mammary development, have focused on IGF-I as the primary mediator of mammary epithelial growth. IGF-II was highly expressed in individual cells along the ductal epithelium by late pubertal stages and through pregnancy-induced growth. It is of potential interest that immunodetection of EGF in pubertal mammary glands in mice showed a similar nonuniform pattern of EGF in luminal epithelial cells along the ducts (34) .
Comparison of the single cell expression of IGF-II at midpregnancy with the pattern of cells identified by a short pulse of BrdU showed a similar pattern of isolated epithelial cells along the ductal structure. Because data presented here, as well as previously published data (6) , have demonstrated mRNA expression of the milk protein genes in developing alveoli, and not ductal cells at this stage, these data support a potential autocrine or paracrine role for IGF-II as a mitogen for specific cells along the ducts. This hypothesis is further supported by the results from IGF-II overexpression in mammary glands of transgenic mice that demonstrate hyperproliferation of the mammary epithelium (55) . However, because the IGF-IR is expressed throughout the ductal epithelium, and because IGF-I is expressed in the stroma at these stages and is present at high levels in the circulation, we cannot rule out the possibility that stromal or circulating IGF-I mediates epithelial growth during late puberty and in pregnancy. Analyzes of mammary glands from IGF-II null mutant mice are in progress in our laboratory and will provide a direct test of an essential function for IGF-II in mammary development. Though it is known that these mice are lactationally competent (56) , it is possible that they might show mild deficits in mammary epithelial growth or differentiation that do not compromise the ability to support litters.
Finally, our results demonstrating high levels of mRNA expression for both IGF ligands and the IGF-IR in mammary epithelium and in the TEBs in particular suggest the possibility that locally produced IGFs could be involved in the proposed role of IGFs and the IGF-IR in estrogen-mediated TEB growth and in breast cancer. Estrogen receptor null mutant mice lack TEBs and demonstrate severely reduced epithelial growth during puberty (3). As discussed previously, IGF-I can synergize with estrogen in promoting ductal growth in pubertal glands (29) and can induce transcription of the estrogen receptor in breast cancer cell lines in vitro (30) . That interactions between estrogen and the IGF system may be an important component of breast tumorigenesis is suggested by the following studies: 1) estrogen induces IGF-IR expression in breast tumor epithelial cell lines (57); and 2) high levels of both the estrogen receptor and the IGF-IR are correlated with susceptibility to breast cancer in humans (58, 59) . The structure that is most susceptible to tumor formation in breast tissue is the TEB in rodents and the equivalent structure in the terminal ductal lobule unit in humans (2, 53, 54, 60) . This is likely because of the high proliferative rates and low percentage of cell death in the TEBs, particularly in the outer, cap cell layer. Therefore, changes in the genome of these cells are more likely to be transmitted to daughter cells, resulting in transformation and tumors. In addition to the fact that IGF-I and IGF-II are among the most potent mitogens for breast cancer cell lines and for primary breast tumors in both humans and rodents, IGF-II and the IGF-IR specifically have been connected to malignancy and breast cancer. Overexpression of IGF-II in breast epithelial cells in vitro results in a malignant phenotype (61) , and genetic overexpression of IGF-II in mouse mammary glands results in a high incidence of breast tumors (55) . Consistent with these results, recent studies in breast cancer patients have confirmed abnormally high levels of IGF-II in the stroma of invasive breast tumors, closely associated with malignant epithelial cells (62) . Moreover, numerous studies have demonstrated that blockade of the IGF-IR inhibits growth of breast tumor cells both in vitro and in vivo (20, 58, (63) (64) (65) (66) . Taken together, these studies, along with the data presented here, support a role for endogenous IGFs in proliferation and survival of mammary epithelial cells and suggest possible mechanisms for IGF function in estrogen-responsive breast cancer.
